



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 15 JULY 2021

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting noting that, due to the COVID-19 pandemic, the meeting was being held via MS Teams. It was noted that a quorum had been achieved.

Written questions from members and answers had been published in advance of the meeting and had been embedded within the meeting papers.

2. Action Log

Members received an update on progress against the action log and **noted** the updates.

3. Managing Director's Report

Members received the Managing Director's Report and **noted** updates on:

- All Wales Positron Emission Tomography (PET) Programme Business Case,
- Ty Llidiard Escalation Review,
- Status Report on Annual Audit of Accounts 2020-2021

4. Funding Release for the Sustainability of the Medical Workforce for the Neuropsychiatry Service (Phase 1)

Members received a report requesting approval for the release of funding to implement (Integrated Commissioning Plan (ICP) 2021-22) to appoint a second Neuropsychiatry Consultant for the All Wales Neuropsychiatry Service to address the immediate fragility of the service to ensure sustainability, and improve patient outcomes. This scheme is phase 1 of the five year plan for the service. Members noted that the scheme was prioritised by the WHSSC Clinical Impact Assessment Group (CIAG) and received the fourth highest score across all the schemes.

Members (1) **approved** the release of funding for the appointment of an additional Consultant Neuropsychiatrist for the Welsh Neuropsychiatry Service; and (2) **noted** that this was phase 1 of a 5 year plan and that a

phase 2 scheme will be submitted to the WHSSC Clinical Impact Assessment Group (CIAG) Prioritisation Process ICP 2022-2025.

5. Funding Release for Implementation of 2021-22 Paediatric Rheumatology – Phase 2

Members received a report requesting support for the release of funding to enable implementation of the 2021-22 ICP scheme for the development of the Paediatric Rheumatology service in south Wales.

Members (1) **noted** the implementation of phase 1 of the Paediatric Rheumatology scheme, (2) **supported** the release of funding for approval by Management Group for the ICP scheme for the development of paediatric Rheumatology services in south Wales; and (3) **noted** that the requested funding is within the provision made for paediatric rheumatology within the ICP 2021-24.

6. Sustainability of South Wales Paediatric Neurology – Funding Release for Implementation of 2021-22 ICP scheme

Members received a report requesting support for the release of funding to enable implementation of the 2021-22 ICP scheme for the sustainability of paediatric neurology services in south Wales.

Members (1) **supported** the release of funding over two phases; (2) **supported** the release of funding for approval by Management Group for the ICP scheme for the sustainability of paediatric neurology services in south Wales; and (3) **noted** that the requested funding is within the provision made for paediatric neurology within the ICP 2021-24.

7. Clinical Impact Assessment Group (CIAG) Funding 2021-22

Members received a report outlining the process for the allocation of funding related to the 2021-22 Clinical Impact Assessment Group (CIAG) schemes identified within the £1.5m agreed by Joint Committee within the plan. Which:

- Offered a reminder of the CIAG process and initial financial assessment,
- Outlined the initial profiling of the schemes,
- Demonstrated how these were further profiled against potential in year risks,
- Specifically outlined how the £1.5m will be allocated

Members **discussed** their understanding of the £1.5 million scheme, the mid-year and full year effect and recurrent funding requirements.

Members received assurance that each scheme would be considered on a scheme by scheme basis and that the correct governance processes had been followed. Members **noted** that:

- the CIAG prioritisation day to inform the 2021-22 Integrated Commissioning Plan took place on 8 October 2020,
- members of the management group received a presentation on the ICP on the 21 January 2021,

- On the 16 February 2021, the Joint Committee noted that the ICP had been through comprehensive and robust development procedures, including horizon scanning, the CIAG Prioritisation Process and Management Group's scrutiny and their resulting recommendations coupled with consideration of the key strategic priorities for WHSSC for 2021-22. The Joint Committee approved the ICP for Specialised Services for 2021-22, subject to the strengthening of section 9 of the ICP,
- On the 9 March 2021 the Joint Committee received and supported the final version of the ICP that reflected the changes agreed by the Joint Committee on 16 February 2021.

Some Members requested time to seek clarification on funding agreements for the ICP plan with their respective finance teams, and agreed to confirm the position to WHSSC by 12 noon on Wednesday 21 July 2021. Members **noted** that the Managing Director would issue a guidance note to members to support their understanding of the process.

Members **noted** the report as the basis for funding releases that will follow.

8. Inherited Cardiac Conditions

Members received a report requesting approval for the release of funding to enable implementation of the 2021-22 ICP Scheme for Inherited Cardiac Conditions (ICC). This investment will enable the continued funding for the South West Wales Inherited Cardiac Conditions service following the end of 2 year British Heart Foundation funding and to ensure ongoing sustainability of the service, reducing inequity. The requested funding is within the provision made for ICC in the ICP 2021-22.

Members (1) **approved** the release of funding for the ICP Scheme for Inherited Cardiac Conditions Screening Service in South West Wales, (pending receipt of confirmation from individual Health Board finance teams on the ICP allocation by 12 noon 21 July 2021); and (2) **noted** that the requested funding was within the provision made for ICC in the ICP 2021-24.

9. Sarcoma Radiology Funding Release

Members received a report requesting support for the release of funding to enable implementation of the 2021-22 ICP scheme for the sustainability of radiology support for the south Wales soft tissue sarcoma MDT. This scheme was prioritised below the line for full funding in 2021-22. However, it is proposed that in view of the relatively small investment required for this scheme and its highly specific focus on radiology sustainability (without scope for phasing), funding is released for the full value of the scheme.

Members (1) **supported** the release of funding for the ICP scheme for the sustainability of radiology support for the south Wales soft tissue

sarcoma MDT (pending receipt of confirmation from individual Health Board finance teams on the ICP allocation by 12 noon 21 July 2021); and (2) **noted** that the requested funding is within the provision made for sarcoma within the ICP 2021-22.

10. Welsh Gender Service Funding Release

Members received a report requesting approval for the release of funding to enable implementation of the 2021-22 ICP Scheme for the All Wales Welsh Gender Service (WGS). The Welsh Gender Team has proposed a 3 year, phased investment to meet growing demand and develop the service towards a sustainable model:

- Phase 1 will focus on increasing capacity and volume of activity for new first appointments through the permanent recruitment of additional Gender Specialists and developing local expertise of trans and gender diverse healthcare through training, development and shadowing opportunities for staff based in Health Boards across Wales;
- Phase 2 will focus on increasing follow up capacity and developing a satellite clinic in North Wales; and
- Phase 3 will uplift the clinical workforce establishment to sustain the Welsh Gender Service and implementation of local hubs in Health Board's across Wales to provide an All Wales Gender Identity Clinic service.

The report requested approval to release funding for phase 1 of the scheme.

Members **approved** the release of funding for phase 1 of the Welsh Gender Service Scheme submitted to the ICP Prioritisation process for 2021- 22 (pending receipt of confirmation from individual Health Board finance teams on the ICP allocation by 12 noon 21 July 2021).

11. COVID-19 Activity Report for Month 2 2021-2022

Members received a report highlighting the scale of the decrease in activity levels during the COVID-19 period, and whether there are any signs of recovery in specialised services activity. These activity decreases were shown in the context of the potential risk regarding patient harms and of the loss of value from nationally agreed financial block contract arrangements.

Members **noted** the report.

12. Financial Performance Report - Month 3 2021-22

Members received a paper the purpose of which was to provide the current financial position of WHSSC together with the outturn forecast for the financial year. The financial position reported at Month 3 for WHSSC is a year-end outturn under spend of £4,237k.

The majority of this under spend relates to the English SLA forecast underspend which reflects the difference between the plan baseline and

the agreed blocks for Q1 & Q2, 2020-21 reserve releases and development slippage. There is a partial offset with the over spend in Independent Patient Funding Requests (IPFR's) and Mental Health that includes high Children and Adolescent Mental Health Services (CAMHS) out of area assessment (OOA) activity and an exceptional high cost medium secure patient.

Members **noted** the report.

